C

이연제약

102460KOSPI

50.0 / 100

Reference Date: 2026-10-23

Financial Score16.5 / 40
News Sentiment12.5 / 25
Momentum9.0 / 20
Disclosure12.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Slightly down 2.7% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Il Yeon Pharm is a specialized pharmaceutical company established in 1964, focusing on the manufacturing and sales of prescription drugs, original pharmaceuticals (e.g., CT contrast agent 'Optirey'), and bulk drugs. Its Chungju facility, certified for biopharmaceutical production and CMO services, supports new drug pipeline development through a production-platform-based R&D model. However, as of 2024, the company reported sales of 145.9 billion won, an operating loss of 30.3 billion won, and a net loss of 29.6 billion won, indicating the need for improved profitability.

Number of Employees

457people

Average Salary

76.4M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 15.004.0Point
PBR
0.83Industry Average 1.205.5Point

Lower than industry avg (good)

ROE
-12.60Industry Average 8.000.0Point

Well below industry avg

Debt Ratio
46.08Industry Average 100.006.5Point

Half of industry avg (excellent)

Trend 2023~20250.5 / 10 points
Revenue Growth Rate
0.5 / 3

Avg ▼1.7% (2-year basis)

Operating Profit Growth Rate
0.0 / 3

Avg ▼19193.7% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -3.2% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 9,790Won52-week high 12,57052-week low 9,770
1-month return2.0Point

1m -2.68% (slight drop)

Volume trend6.0Point

Volume increasing

Detailed Disclosure

10 totalPositive 1Neutral 9Negative 0
  • Neutral주식등의대량보유상황보고서(약식)2026-10-20
  • Neutral전환가액ㆍ신주인수권행사가액ㆍ교환가액의조정(안내공시)2026-10-16
  • Positive유상증자또는주식관련사채등의발행결과(자율공시)2026-10-16
  • Neutral[기재정정]주요사항보고서(전환사채권발행결정)2026-10-13
  • Neutral주요사항보고서(전환사채권발행결정)2026-10-08